Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 74 | 2023 | 1236 | 7.640 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 37 | 2023 | 1659 | 3.330 |
Why?
|
Radiotherapy Dosage | 45 | 2023 | 2896 | 1.890 |
Why?
|
Genital Neoplasms, Female | 8 | 2023 | 533 | 1.480 |
Why?
|
Catheters | 11 | 2023 | 421 | 1.300 |
Why?
|
Radiometry | 16 | 2020 | 813 | 1.190 |
Why?
|
Prostatic Neoplasms | 40 | 2021 | 11336 | 1.090 |
Why?
|
Rectum | 14 | 2017 | 895 | 0.940 |
Why?
|
Iodine Radioisotopes | 10 | 2012 | 1032 | 0.900 |
Why?
|
Radiation Dosage | 8 | 2017 | 1956 | 0.720 |
Why?
|
Organs at Risk | 4 | 2017 | 358 | 0.580 |
Why?
|
Gold | 5 | 2014 | 479 | 0.580 |
Why?
|
Film Dosimetry | 3 | 2020 | 29 | 0.570 |
Why?
|
Prostate | 12 | 2021 | 1791 | 0.520 |
Why?
|
Radiotherapy, Conformal | 7 | 2011 | 549 | 0.520 |
Why?
|
Needles | 2 | 2022 | 451 | 0.500 |
Why?
|
Magnetic Resonance Imaging | 32 | 2023 | 36285 | 0.500 |
Why?
|
Metal Nanoparticles | 3 | 2014 | 396 | 0.480 |
Why?
|
Software Validation | 1 | 2014 | 59 | 0.480 |
Why?
|
Uterine Cervical Neoplasms | 9 | 2021 | 2016 | 0.470 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2015 | 471 | 0.450 |
Why?
|
Electromagnetic Phenomena | 1 | 2014 | 161 | 0.440 |
Why?
|
Urinary Bladder | 8 | 2017 | 1166 | 0.430 |
Why?
|
Phantoms, Imaging | 10 | 2022 | 2509 | 0.400 |
Why?
|
Uncertainty | 2 | 2014 | 751 | 0.370 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2010 | 345 | 0.370 |
Why?
|
Drug Implants | 3 | 2016 | 230 | 0.360 |
Why?
|
Artifacts | 7 | 2015 | 1897 | 0.360 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2017 | 881 | 0.350 |
Why?
|
Radiation Injuries | 6 | 2010 | 1182 | 0.340 |
Why?
|
Colon, Sigmoid | 5 | 2017 | 124 | 0.330 |
Why?
|
Quality Control | 4 | 2019 | 825 | 0.330 |
Why?
|
Catheterization | 2 | 2012 | 1426 | 0.320 |
Why?
|
Imaging, Three-Dimensional | 7 | 2015 | 4048 | 0.310 |
Why?
|
Monte Carlo Method | 4 | 2009 | 1256 | 0.300 |
Why?
|
Strontium Radioisotopes | 2 | 2004 | 18 | 0.290 |
Why?
|
Radiation Protection | 3 | 2010 | 425 | 0.280 |
Why?
|
Models, Theoretical | 4 | 2017 | 3561 | 0.280 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2014 | 8946 | 0.270 |
Why?
|
Radiotherapy, Computer-Assisted | 4 | 2014 | 90 | 0.260 |
Why?
|
Tomography, X-Ray Computed | 16 | 2021 | 20500 | 0.260 |
Why?
|
Algorithms | 11 | 2021 | 13959 | 0.260 |
Why?
|
Quality Assurance, Health Care | 3 | 2017 | 2167 | 0.260 |
Why?
|
Prostheses and Implants | 3 | 2013 | 1270 | 0.240 |
Why?
|
Magnetic Resonance Imaging, Interventional | 3 | 2017 | 187 | 0.230 |
Why?
|
Iridium Radioisotopes | 1 | 2004 | 26 | 0.230 |
Why?
|
Models, Biological | 5 | 2014 | 9461 | 0.230 |
Why?
|
Pattern Recognition, Automated | 3 | 2014 | 994 | 0.210 |
Why?
|
Radiotherapy | 3 | 2011 | 1504 | 0.200 |
Why?
|
Fiducial Markers | 2 | 2014 | 132 | 0.190 |
Why?
|
Feasibility Studies | 7 | 2021 | 5199 | 0.190 |
Why?
|
Uterine Neoplasms | 3 | 2017 | 1439 | 0.180 |
Why?
|
Catheters, Indwelling | 2 | 2014 | 428 | 0.180 |
Why?
|
Ultrasonography, Interventional | 2 | 2014 | 1489 | 0.180 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 801 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2012 | 3339 | 0.180 |
Why?
|
Radiography, Interventional | 1 | 2008 | 1112 | 0.180 |
Why?
|
Coronary Restenosis | 1 | 2003 | 396 | 0.180 |
Why?
|
Graft Occlusion, Vascular | 1 | 2004 | 537 | 0.180 |
Why?
|
Humans | 91 | 2023 | 758381 | 0.170 |
Why?
|
Breast | 2 | 2008 | 1963 | 0.170 |
Why?
|
Prostate-Specific Antigen | 7 | 2019 | 2528 | 0.170 |
Why?
|
Electrical Equipment and Supplies | 1 | 2019 | 28 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2019 | 9273 | 0.160 |
Why?
|
Vaginal Neoplasms | 2 | 2012 | 104 | 0.160 |
Why?
|
Reproducibility of Results | 12 | 2015 | 20052 | 0.150 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1134 | 0.150 |
Why?
|
Calibration | 4 | 2019 | 814 | 0.140 |
Why?
|
Adenocarcinoma | 6 | 2016 | 6313 | 0.140 |
Why?
|
Sensitivity and Specificity | 9 | 2014 | 14641 | 0.140 |
Why?
|
Immobilization | 2 | 2012 | 227 | 0.140 |
Why?
|
Nanoparticles | 3 | 2016 | 1940 | 0.140 |
Why?
|
Research Report | 1 | 2019 | 367 | 0.140 |
Why?
|
Eye Neoplasms | 1 | 1998 | 306 | 0.130 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2016 | 66 | 0.130 |
Why?
|
Biopsy, Needle | 2 | 2001 | 1630 | 0.130 |
Why?
|
Equipment Design | 4 | 2017 | 3507 | 0.130 |
Why?
|
Retinoblastoma | 1 | 1998 | 317 | 0.130 |
Why?
|
Numerical Analysis, Computer-Assisted | 2 | 2006 | 119 | 0.130 |
Why?
|
Male | 44 | 2021 | 358742 | 0.120 |
Why?
|
Phthalazines | 1 | 2017 | 382 | 0.120 |
Why?
|
Nanocapsules | 1 | 2015 | 92 | 0.110 |
Why?
|
Silicon Dioxide | 1 | 2015 | 216 | 0.110 |
Why?
|
Fluorescence | 1 | 2016 | 749 | 0.110 |
Why?
|
Technology, Radiologic | 2 | 2007 | 160 | 0.110 |
Why?
|
Electrons | 1 | 2014 | 264 | 0.110 |
Why?
|
Chitosan | 2 | 2010 | 131 | 0.100 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13245 | 0.100 |
Why?
|
Urinary Retention | 2 | 2005 | 106 | 0.100 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2211 | 0.100 |
Why?
|
Surface Properties | 2 | 2012 | 1159 | 0.100 |
Why?
|
Software | 4 | 2021 | 4416 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2012 | 512 | 0.100 |
Why?
|
Retrospective Studies | 16 | 2021 | 80170 | 0.100 |
Why?
|
Air | 1 | 2012 | 186 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 668 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2912 | 0.090 |
Why?
|
Gamma Rays | 1 | 2012 | 317 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1113 | 0.090 |
Why?
|
Computer Simulation | 7 | 2014 | 6201 | 0.090 |
Why?
|
Piperazines | 2 | 2017 | 2511 | 0.090 |
Why?
|
Skin Diseases | 1 | 2020 | 1088 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2012 | 1791 | 0.090 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2016 | 739 | 0.090 |
Why?
|
Female | 28 | 2023 | 390316 | 0.090 |
Why?
|
Risk Assessment | 4 | 2019 | 23883 | 0.090 |
Why?
|
Metals | 1 | 2014 | 717 | 0.080 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1228 | 0.080 |
Why?
|
Prospective Studies | 11 | 2021 | 54136 | 0.080 |
Why?
|
Water | 1 | 2015 | 1402 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 510 | 0.080 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 228 | 0.080 |
Why?
|
Polyglycolic Acid | 1 | 2010 | 405 | 0.080 |
Why?
|
Breast Neoplasms | 4 | 2010 | 21017 | 0.080 |
Why?
|
Light | 1 | 2014 | 1345 | 0.080 |
Why?
|
Cisplatin | 1 | 2014 | 1645 | 0.080 |
Why?
|
Dental Restoration, Permanent | 1 | 2009 | 128 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2007 | 1110 | 0.080 |
Why?
|
X-Ray Film | 1 | 2008 | 31 | 0.080 |
Why?
|
Treatment Outcome | 13 | 2018 | 64379 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2016 | 4023 | 0.070 |
Why?
|
Vagina | 3 | 2010 | 838 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3891 | 0.070 |
Why?
|
Endometrial Neoplasms | 2 | 2008 | 1357 | 0.070 |
Why?
|
Drug Approval | 1 | 2014 | 809 | 0.070 |
Why?
|
Organ Size | 1 | 2012 | 2252 | 0.070 |
Why?
|
Apoptosis | 1 | 2023 | 9468 | 0.070 |
Why?
|
Transistors, Electronic | 1 | 2007 | 21 | 0.070 |
Why?
|
Urethra | 3 | 2008 | 406 | 0.070 |
Why?
|
Robotics | 1 | 2014 | 874 | 0.070 |
Why?
|
Thoracic Neoplasms | 1 | 2009 | 266 | 0.070 |
Why?
|
Rectal Diseases | 1 | 2007 | 144 | 0.070 |
Why?
|
HeLa Cells | 1 | 2012 | 3096 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 1660 | 0.070 |
Why?
|
Skin Physiological Phenomena | 1 | 2007 | 188 | 0.070 |
Why?
|
Motion | 2 | 2006 | 779 | 0.070 |
Why?
|
Drug Carriers | 1 | 2010 | 705 | 0.070 |
Why?
|
Delayed-Action Preparations | 1 | 2009 | 961 | 0.060 |
Why?
|
Radiography | 3 | 2006 | 6955 | 0.060 |
Why?
|
Peer Review | 1 | 2008 | 217 | 0.060 |
Why?
|
Aged | 24 | 2019 | 168217 | 0.060 |
Why?
|
Survival Rate | 3 | 2019 | 12721 | 0.060 |
Why?
|
Movement | 1 | 2012 | 1474 | 0.060 |
Why?
|
Lactic Acid | 1 | 2010 | 1133 | 0.060 |
Why?
|
Computer Systems | 3 | 2003 | 470 | 0.060 |
Why?
|
Body Burden | 1 | 2005 | 158 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5246 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2322 | 0.060 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2006 | 240 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2009 | 1268 | 0.060 |
Why?
|
Carcinoma | 2 | 2007 | 2330 | 0.060 |
Why?
|
Finite Element Analysis | 1 | 2006 | 428 | 0.060 |
Why?
|
Mediastinal Neoplasms | 1 | 2006 | 402 | 0.060 |
Why?
|
Beta Particles | 1 | 2003 | 47 | 0.060 |
Why?
|
Relative Biological Effectiveness | 1 | 2005 | 312 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 1214 | 0.050 |
Why?
|
Middle Aged | 24 | 2019 | 219560 | 0.050 |
Why?
|
Medical Errors | 1 | 2011 | 1255 | 0.050 |
Why?
|
Ultrasonography | 2 | 2014 | 5952 | 0.050 |
Why?
|
Rotation | 2 | 2008 | 514 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2023 | 282 | 0.050 |
Why?
|
Yttrium Radioisotopes | 1 | 2003 | 107 | 0.050 |
Why?
|
Self Medication | 1 | 2002 | 117 | 0.050 |
Why?
|
Watchful Waiting | 2 | 2018 | 509 | 0.050 |
Why?
|
Niacin | 1 | 2002 | 118 | 0.050 |
Why?
|
User-Computer Interface | 2 | 2017 | 1397 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3806 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2018 | 39060 | 0.050 |
Why?
|
Biophysical Phenomena | 2 | 2001 | 320 | 0.050 |
Why?
|
Biophysics | 2 | 2001 | 380 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2017 | 58681 | 0.040 |
Why?
|
Neoplasm Staging | 5 | 2018 | 11152 | 0.040 |
Why?
|
Organ Specificity | 1 | 2005 | 1955 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8823 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6493 | 0.040 |
Why?
|
Prostatic Hyperplasia | 2 | 2000 | 530 | 0.040 |
Why?
|
Urination Disorders | 1 | 2000 | 240 | 0.040 |
Why?
|
Neoplasms | 4 | 2014 | 22030 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 781 | 0.040 |
Why?
|
Perineum | 1 | 2000 | 208 | 0.040 |
Why?
|
Cell Death | 1 | 2023 | 1667 | 0.040 |
Why?
|
Drug Interactions | 1 | 2002 | 1414 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2004 | 793 | 0.040 |
Why?
|
Kinetics | 2 | 2019 | 6371 | 0.040 |
Why?
|
Head and Neck Neoplasms | 2 | 2009 | 2882 | 0.040 |
Why?
|
Automation | 1 | 2020 | 581 | 0.040 |
Why?
|
Risk Factors | 6 | 2018 | 73806 | 0.040 |
Why?
|
Scattering, Radiation | 1 | 1998 | 488 | 0.030 |
Why?
|
Lens, Crystalline | 1 | 1998 | 388 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15646 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12440 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10747 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 39873 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13591 | 0.030 |
Why?
|
Image Enhancement | 3 | 2014 | 2880 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 850 | 0.030 |
Why?
|
Prostatectomy | 1 | 2003 | 1956 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2017 | 480 | 0.030 |
Why?
|
Vascular Diseases | 1 | 2003 | 1160 | 0.030 |
Why?
|
Mammaplasty | 1 | 2005 | 1239 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 2004 | 2189 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7377 | 0.030 |
Why?
|
Diffusion | 1 | 2016 | 813 | 0.030 |
Why?
|
Mammography | 1 | 2005 | 2427 | 0.030 |
Why?
|
Animals | 7 | 2023 | 167777 | 0.030 |
Why?
|
Adult | 8 | 2017 | 219916 | 0.030 |
Why?
|
Risk Management | 1 | 2017 | 557 | 0.030 |
Why?
|
Electromagnetic Fields | 1 | 2014 | 296 | 0.030 |
Why?
|
Computer Graphics | 1 | 2014 | 340 | 0.030 |
Why?
|
Nanostructures | 1 | 2017 | 547 | 0.030 |
Why?
|
Chickens | 1 | 2014 | 860 | 0.020 |
Why?
|
Particle Size | 1 | 2016 | 1641 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2006 | 2551 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5892 | 0.020 |
Why?
|
Boston | 2 | 2017 | 9304 | 0.020 |
Why?
|
Nanomedicine | 1 | 2014 | 288 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3758 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 29558 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81107 | 0.020 |
Why?
|
Equipment Failure | 1 | 2013 | 578 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6821 | 0.020 |
Why?
|
Radiation Oncology | 1 | 2017 | 563 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2014 | 2263 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1893 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2017 | 1147 | 0.020 |
Why?
|
Fluoresceins | 1 | 2010 | 234 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 290 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2010 | 131 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3602 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16886 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5861 | 0.020 |
Why?
|
Intraoperative Care | 2 | 2003 | 766 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 245 | 0.020 |
Why?
|
Dental Amalgam | 1 | 2009 | 65 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 398 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3574 | 0.020 |
Why?
|
Nanotechnology | 1 | 2014 | 707 | 0.020 |
Why?
|
Dental Materials | 1 | 2009 | 113 | 0.020 |
Why?
|
Mastectomy | 2 | 2008 | 1832 | 0.020 |
Why?
|
Biopsy | 1 | 2000 | 6768 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2011 | 424 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4901 | 0.020 |
Why?
|
Mediastinum | 1 | 2009 | 266 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2600 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Quality of Life | 1 | 2009 | 13286 | 0.020 |
Why?
|
Retina | 1 | 1998 | 2637 | 0.020 |
Why?
|
X-Rays | 1 | 1987 | 307 | 0.020 |
Why?
|
Fecal Incontinence | 1 | 2009 | 241 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2640 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 875 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 451 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2925 | 0.020 |
Why?
|
Online Systems | 1 | 2006 | 181 | 0.020 |
Why?
|
Postoperative Care | 1 | 2012 | 1471 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2009 | 424 | 0.020 |
Why?
|
Urinary Incontinence | 1 | 2009 | 495 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 843 | 0.010 |
Why?
|
Tongue Neoplasms | 1 | 2006 | 183 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 1007 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2209 | 0.010 |
Why?
|
Life Tables | 1 | 2003 | 365 | 0.010 |
Why?
|
Pelvis | 1 | 2008 | 743 | 0.010 |
Why?
|
Preoperative Care | 2 | 2002 | 2249 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 462 | 0.010 |
Why?
|
Precipitating Factors | 1 | 2002 | 51 | 0.010 |
Why?
|
Ejaculation | 1 | 2002 | 59 | 0.010 |
Why?
|
Proctitis | 1 | 2002 | 41 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 266 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.010 |
Why?
|
Prothrombin Time | 1 | 2002 | 116 | 0.010 |
Why?
|
Feedback | 1 | 2006 | 791 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2690 | 0.010 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1096 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 42058 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23341 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9599 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4317 | 0.010 |
Why?
|
Peritoneum | 1 | 2000 | 224 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 1185 | 0.010 |
Why?
|
Odds Ratio | 1 | 2011 | 9650 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3527 | 0.010 |
Why?
|
Sarcoma | 1 | 2009 | 1785 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18125 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 2002 | 642 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2008 | 3485 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2002 | 907 | 0.010 |
Why?
|
Young Adult | 2 | 2016 | 58808 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13276 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11709 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3617 | 0.010 |
Why?
|
Heart | 1 | 2008 | 4382 | 0.010 |
Why?
|
Child | 1 | 2023 | 79813 | 0.010 |
Why?
|
United States | 2 | 2014 | 72140 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 87888 | 0.010 |
Why?
|
Acute Disease | 1 | 2005 | 7225 | 0.010 |
Why?
|
Pilot Projects | 1 | 2006 | 8554 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5070 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2003 | 2821 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 7985 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6233 | 0.010 |
Why?
|
Regression Analysis | 1 | 2000 | 6353 | 0.010 |
Why?
|
Lung | 1 | 2008 | 9985 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 12951 | 0.000 |
Why?
|
Patient Selection | 1 | 1998 | 4244 | 0.000 |
Why?
|